Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

BGLC

BioNexus Gene Lab (BGLC)

BioNexus Gene Lab Corporation
Von:
Sortieren nach:
 Showing the most relevant articles for your search:NASDAQ:BGLC
DatumZeitQuelleÜberschriftSymbolFirma
31/05/202421h47Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:BGLCBioNexus Gene Lab Corporation
31/05/202421h46Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:BGLCBioNexus Gene Lab Corporation
31/05/202421h46Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:BGLCBioNexus Gene Lab Corporation
31/05/202421h45Edgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:BGLCBioNexus Gene Lab Corporation
31/05/202421h45Edgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:BGLCBioNexus Gene Lab Corporation
09/05/202418h37Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGLCBioNexus Gene Lab Corporation
18/04/202420h52GlobeNewswire Inc.BioNexus Gene Lab Corp. Agrees to Invest RM 1.2 million in Ascension Innovation (AISB) to Advance Digital Health Innovation through AI adoption in HealthcareNASDAQ:BGLCBioNexus Gene Lab Corporation
26/01/202422h05Edgar (US Regulatory)Form PRE 14C - Other preliminary information statementsNASDAQ:BGLCBioNexus Gene Lab Corporation
23/01/202413h55Edgar (US Regulatory)Form SC 13G - Statement of acquisition of beneficial ownership by individualsNASDAQ:BGLCBioNexus Gene Lab Corporation
03/11/202315h55Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGLCBioNexus Gene Lab Corporation
07/09/202317h17Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGLCBioNexus Gene Lab Corporation
24/07/202323h28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BGLCBioNexus Gene Lab Corporation
24/07/202317h30GlobeNewswire Inc.BioNexus Gene Lab Corp. Announces Closing of $5.75 Million Public Offering and Full Exercise of Over-Allotment Option and Uplisting to the Nasdaq Capital MarketNASDAQ:BGLCBioNexus Gene Lab Corporation
20/07/202319h29GlobeNewswire Inc.BioNexus Gene Lab Corp. Announces Pricing of $5 Million Public Offering and Uplisting to the Nasdaq Capital MarketNASDAQ:BGLCBioNexus Gene Lab Corporation
 Showing the most relevant articles for your search:NASDAQ:BGLC

Kürzlich von Ihnen besucht

Delayed Upgrade Clock